Biology:Olpasiran
From HandWiki
Olpasiran (AMG890) is an experimental antisense therapy designed to lower the level of lipoprotein(a), which is believed to be a causal factor in the development of cardiovascular disease. The drug is developed by Amgen.[1][2]
References
- ↑ O’Donoghue, Michelle L.; Rosenson, Robert S.; Gencer, Baris; López, J. Antonio G.; Lepor, Norman E.; Baum, Seth J.; Stout, Elmer; Gaudet, Daniel et al. (17 November 2022). "Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease". New England Journal of Medicine 387 (20): 1855–1864. doi:10.1056/NEJMoa2211023.
- ↑ Koren, Michael J.; Moriarty, Patrick Maurice; Baum, Seth J.; Neutel, Joel; Hernandez-Illas, Martha; Weintraub, Howard S.; Florio, Monica; Kassahun, Helina et al. (January 2022). "Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)" (in en). Nature Medicine 28 (1): 96–103. doi:10.1038/s41591-021-01634-w. ISSN 1546-170X. https://www.nature.com/articles/s41591-021-01634-w.
 |  |
